Literature DB >> 22444875

Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives.

Kevin Bonfield1, Erica Amato, Tony Bankemper, Hannah Agard, Jeffrey Steller, James M Keeler, David Roy, Adam McCallum, Stefan Paula, Lili Ma.   

Abstract

Aromatase (CYP19) catalyzes the aromatization reaction of androgen substrates to estrogens, the last and rate-limiting step in estrogen biosynthesis. Inhibition of aromatase is a new and promising approach to treat hormone-dependent breast cancer. We present here the design and development of isoflavanone derivatives as potential aromatase inhibitors. Structural modifications were performed on the A and B rings of isoflavanones via microwave-assisted, gold-catalyzed annulation reactions of hydroxyaldehydes and alkynes. The in vitro aromatase inhibition of these compounds was determined by fluorescence-based assays utilizing recombinant human aromatase (baculovirus/insect cell-expressed). The compounds 3-(4-phenoxyphenyl)chroman-4-one (1h), 6-methoxy-3-phenylchroman-4-one (2a) and 3-(pyridin-3-yl)chroman-4-one (3b) exhibited potent inhibitory effects against aromatase with IC(50) values of 2.4 μM, 0.26 μM and 5.8 μM, respectively. Docking simulations were employed to investigate crucial enzyme/inhibitor interactions such as hydrophobic interactions, hydrogen bonding and heme iron coordination. This report provides useful information on aromatase inhibition and serves as a starting point for the development of new flavonoid aromatase inhibitors.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22444875      PMCID: PMC3933949          DOI: 10.1016/j.bmc.2012.02.042

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  69 in total

1.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.

Authors:  P Ertl; B Rohde; P Selzer
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

2.  A high-throughput screen to identify inhibitors of aromatase (CYP19).

Authors:  D M Stresser; S D Turner; J McNamara; P Stocker; V P Miller; C L Crespi; C J Patten
Journal:  Anal Biochem       Date:  2000-09-10       Impact factor: 3.365

3.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

Authors:  D M Stresser; A P Blanchard; S D Turner; J C Erve; A A Dandeneau; V P Miller; C L Crespi
Journal:  Drug Metab Dispos       Date:  2000-12       Impact factor: 3.922

4.  A novel, broad-spectrum antitumor compound containing the 1-hydroxycyclohexa-2,5-dien-4-one group: the disclosure of a new antitumor pharmacophore in protoapigenone 1.

Authors:  Qianying Yuan; Ziwei Liu; Chaomei Xiong; Liqian Wu; Jianping Wang; Jinlan Ruan
Journal:  Bioorg Med Chem Lett       Date:  2011-04-05       Impact factor: 2.823

Review 5.  Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy.

Authors:  Thomas Efferth; Egon Koch
Journal:  Curr Drug Targets       Date:  2011-01       Impact factor: 3.465

6.  Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.

Authors:  Angela Stefanachi; Angelo D Favia; Orazio Nicolotti; Francesco Leonetti; Leonardo Pisani; Marco Catto; Christina Zimmer; Rolf W Hartmann; Angelo Carotti
Journal:  J Med Chem       Date:  2011-02-22       Impact factor: 7.446

Review 7.  Role of aromatase inhibitors in advanced breast cancer.

Authors:  A U Buzdar
Journal:  Endocr Relat Cancer       Date:  1999-06       Impact factor: 5.678

8.  Structure-based design of potent aromatase inhibitors by high-throughput docking.

Authors:  Fabiana Caporuscio; Giulio Rastelli; Carol Imbriano; Alberto Del Rio
Journal:  J Med Chem       Date:  2011-05-23       Impact factor: 7.446

9.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

Authors:  J M Nabholtz; A Buzdar; M Pollak; W Harwin; G Burton; A Mangalik; M Steinberg; A Webster; M von Euler
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

10.  Novel flavonoids with antiproliferative activities against breast cancer cells.

Authors:  Nianhuan Yao; Chao-Yu Chen; Chun-Yi Wu; Kiyomi Motonishi; Hsing-Jien Kung; Kit S Lam
Journal:  J Med Chem       Date:  2011-06-08       Impact factor: 7.446

View more
  9 in total

Review 1.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

Review 2.  Botanicals and Their Bioactive Phytochemicals for Women's Health.

Authors:  Birgit M Dietz; Atieh Hajirahimkhan; Tareisha L Dunlap; Judy L Bolton
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

3.  Investigation of fluorinated and bifunctionalized 3-phenylchroman-4-one (isoflavanone) aromatase inhibitors.

Authors:  Erica Amato; Tony Bankemper; Rebecca Kidney; Thuy Do; Alma Onate; Fathima Shazna Thowfeik; Edward J Merino; Stefan Paula; Lili Ma
Journal:  Bioorg Med Chem       Date:  2013-12-05       Impact factor: 3.641

4.  Isolation and characterization of new phenolic compounds with estrogen biosynthesis-inhibiting and antioxidation activities from Broussonetia papyrifera leaves.

Authors:  Chunyan Yang; Fu Li; Baowen Du; Bin Chen; Fei Wang; Mingkui Wang
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

5.  Binding mode of triazole derivatives as aromatase inhibitors based on docking, protein ligand interaction fingerprinting, and molecular dynamics simulation studies.

Authors:  Ayyub Mojaddami; Amirhossein Sakhteman; Masood Fereidoonnezhad; Zeinab Faghih; Atena Najdian; Soghra Khabnadideh; Hossein Sadeghpour; Zahra Rezaei
Journal:  Res Pharm Sci       Date:  2017-02

6.  Synthesis, Docking Studies and Biological Activity of New Benzimidazole- Triazolothiadiazine Derivatives as Aromatase Inhibitor.

Authors:  Ulviye Acar Çevik; Betül Kaya Çavuşoğlu; Begüm Nurpelin Sağlık; Derya Osmaniye; Serkan Levent; Sinem Ilgın; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2020-04-02       Impact factor: 4.411

7.  Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design.

Authors:  Sako Mirzaie; Latifeh Chupani; Ebrahim Barzegari Asadabadi; Ahmad Reza Shahverdi; Mostafa Jamalan
Journal:  EXCLI J       Date:  2013-03-11       Impact factor: 4.068

8.  3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein-ligand interactions.

Authors:  Sehan Lee; Mace G Barron
Journal:  J Cheminform       Date:  2018-01-18       Impact factor: 5.514

Review 9.  Estrogen alpha receptor antagonists for the treatment of breast cancer: a review.

Authors:  Deepika Sharma; Sanjiv Kumar; Balasubramanian Narasimhan
Journal:  Chem Cent J       Date:  2018-10-25       Impact factor: 4.215

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.